A prospective randomized study of Chop versus Chop plus Alpha-2B interferon in patients with Intermediate and High Grade non-Hodgkin's lymphoma: The International Oncology Study Group NHL1 study

Leukemia and Lymphoma

Volumn 40, Issue 1-2, 2000, Pages 95-103

  Giles, F J ^a   Shan, J ^a   Advani, S H ^a   Akan, H ^a   Aydogdu, I ^a   Aziz, Z ^a   Azim, H A ^a   Bapsy, P P ^a   Buyukkececi, F ^a   Chaimongkol, B ^a   Chen, P M ^a   Cheong, S K ^a   Ferhanoglu, B ^a   Hamza, R ^a   Khalid, H M ^a   Intragumtornchai, T ^a   Kim, S W ^a   Kim, S Y ^a   Koc, H ^a   Kumar, L ^a   Kumar, R ^a   Lei, K I ^a   Lekhakula, A ^a   Muthalib, A ^a   Patel, M ^a   Poovalingam, V P ^a   Prayoonwiwat, W ^a   Rana, F ^a   Reksodiputro, A H ^a   Ruff, P ^a   Sagar, T G ^a   Schwarer, A P ^a   Song, H S ^a   Suh, C W ^a   Suharti, C ^a   Supindiman, I ^a   Tee, G Y ^a   Thamprasit, T ^a   Villalon, A H ^a   Wickham, N R ^a   Wong, J E ^a   Yalcin, A ^a   Jootar, S ^a   more..

^a International Oncology Study Group   (United States)

Author keywords

Adriamycin; CHOP; CHOP+alpha 2b interferon; Cyclophosphamide; High grade lymphomas; Interferon; Intermediate; International oncology study group; Large cell lymphoma; Non hodgkin's lymphoma; Prednisone; Response; Survival; Vincristine

Indexed keywords

ALLOPURINOL; ALPHA2B INTERFERON; AMIFOSTINE; ANTIINFECTIVE AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; METHOTREXATE; PARACETAMOL; PREDNISONE; PROCARBAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT GROWTH FACTOR; VINCRISTINE;

ADULT; ALOPECIA; ARTICLE; BLOOD TOXICITY; CANCER GRADING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; ENDOCRINE DISEASE; EYE TOXICITY; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL TOXICITY; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; LIVER TOXICITY; LUNG TOXICITY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MUCOSA; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN TOXICITY; SURVIVAL RATE; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 0035141375     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190009054885     Document Type: Article

References (25)

1. The Non-Hodgkin's Lymphoma Pathologic Classification Project
2. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma
3. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non- Hodgkin's lymphoma
4. CHOP versus MACOP-B in aggressive lymphoma-a Nordic Lymphoma Group randomised trial
5. A randomized EPOCH vs. CHOP front-line therapy for aggressive non- Hodgkin's lymphoma patients: Long-term results
6. Recombinant interferon-alpha therapy in patients with follicular lymphoma
7. Report of the Committee on Hodgkin's Disease Staging Classification
8. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma
9. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: Final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial
10. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: A randomized study from the Groupe d'Etude des Lymphomes Folliculaires
11. Quality-of-life-adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma: An aid to clinical decision making
12. Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma
13. Interferon alfa plus chemotherapy for non-Hodgkin's lymphoma: Five-year follow-up
14. A phase I trial of interferon-alpha-2a plus cyclophosphamide, vincristine, prednisone, and doxorubicin
15. Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon
16. Maintenance therapy with interferon alfa 2b in patients with diffuse large cell lymphoma
17. Interferon alpha 2b as maintenance therapy in low grade malignant lymphoma improves duration of remission and survival
18. Interferon as maintenance therapy in refractory malignant lymphoma
19. HIV-related non-Hodgkin's lymphoma: CHOP induction therapy and interferon-alpha-2b/zidovudine maintenance therapy
20. Angioimmunoblastic-like T-cell non Hodgkin's lymphoma: Outcome after chemotherapy in 33 patients and review of the literature
21. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: A dose-finding pilot study
22. Bone marrow protection with amifostine in the treatment of high-risk malignant lymphoma
23. A phase I study of WR-2721 in combination with total body irradiation (TBI) in patients with refractory lymphoid malignancies
24. Early evaluation of liposomal daunorubicin (DaunoXome, Nexstar) in the treatment of relapsed and refractory lymphoma
25. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, dexamethasone (CVXD) regimen in Richter's syndrome